07:00 , Mar 14, 2016 |  BC Week In Review  |  Company News

Immunomedics, UCB deal

Immunomedics said UCB discontinued development of epratuzumab ( IMMU-103 ) and terminated a May 2006 deal that gave UCB exclusive rights to develop and commercialize the compound for autoimmune indications. The humanized mAb targeting CD22...
08:00 , Nov 16, 2015 |  BioCentury  |  Product Development

On SLE's trail

AstraZeneca plc's MedImmune LLC unit is following a clinical development trail for lupus candidate anifrolumab first blazed by Benlysta belimumab. The company hopes that its track record of successful mid-stage trials in the indication have...
07:00 , Oct 5, 2015 |  BioCentury  |  Finance

Drawn and quartered

There was no joy to be had in 3Q15, as every biotech market cap band fell by at least 15%. After the carnage only one group - companies valued north of $5 billion - are...
07:00 , Aug 3, 2015 |  BC Week In Review  |  Clinical News

Epratuzumab: Phase III data

The identical, double-blind, international Phase III EMBODY 1 and 2 trials in patients with moderate to severe SLE showed that once-weekly 600 mg epratuzumab for 4 weeks and 1,200 mg epratuzumab every 2 weeks for...
07:00 , Aug 3, 2015 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes Analyst picks & changes Company Bank Analyst Coverage Opinion Wk chg 7/31 cls Aegerion Pharmaceuticals Inc. (NASDAQ:AEGR) Jefferies Eun Yang Upgrade Buy (from hold) 9% $19.13 Yang upgraded, saying the resignation...
01:44 , Jul 29, 2015 |  BC Extra  |  Clinical News

Immunomedics falls on Phase III miss in lupus

Immunomedics Inc. (NASDAQ:IMMU) sank $1.16 (31%) to $2.55 after partner UCB Group (Euronext:UCB) said epratuzumab missed its primary endpoints in the identical Phase III EMBODY 1 and EMBODY 2 trials to treat systemic lupus erythematosus...
03:06 , Oct 3, 2014 |  BC Extra  |  Clinical News

Lilly halts tabalumab for lupus

Eli Lilly and Co. (NYSE:LLY) said it will discontinue development of tabalumab to treat systemic lupus erythematosus (SLE) because it failed to show sufficient efficacy in two Phase III trials. The pharma said its decision...
01:30 , May 3, 2014 |  BC Extra  |  Financial News

Immunomedics raises $30.2 million in follow-on

Immunomedics Inc. (NASDAQ:IMMU) raised $30.2 million through the sale of 9 million shares at $3.35 in a follow-on underwritten by Wells Fargo Securities and Jefferies. Immunomedics proposed the follow-on late Thursday, when its share price...
00:10 , May 2, 2014 |  BC Extra  |  Financial News

Immunomedics planning follow-on

Immunomedics Inc. (NASDAQ:IMMU) proposed a follow-on late Thursday underwritten by Wells Fargo Securities and Jefferies. Immunomedics' most advanced internal program, Yttrium-90-clivatuzumab tetraxetan (formerly IMMU-107 ), is in the Phase III PANCRIT-1 trial to treat metastatic...
07:00 , Sep 2, 2013 |  BC Week In Review  |  Clinical News

Epratuzumab: Phase III ongoing

Immunomedics said it now expects first results in 1Q15 after reporting slower-than-expected patient recruitment in the double-blind, placebo-controlled, international Phase III EMBODY 1 and 2 trials of IV epratuzumab in about 780 patients each. The...